OpenAI Codex v0.114.0 (research preview)
--------
workdir: /Users/junekim/Documents/universal-diagnosis
model: gpt-5.4
provider: openai
approval: never
sandbox: read-only
reasoning effort: none
reasoning summaries: none
session id: 019d0d3e-4d07-74c1-a5ca-af378a9b20cd
--------
user
Merge these event-based search reports into a SOAP note for aTyr Pharma (ATYR). This is Run 1 — a REAL prospective prediction. The outcome is NOT known.

Catalyst: aTyr announces a new sarcoidosis clinical trial (any phase, any design) by 2026-09-30. PASS = press release or 8-K announcing new trial. FAIL = no such announcement by window end.

Shkreli is short, predicted 80% crash (which already happened — stock -83% on Phase 3 miss).

Company IS the consolidate stack for efzofitimod. The Phase 3 missed primary but hit secondaries. FDA Type C meeting mid-April 2026 is the gating event.

Output: S (one paragraph), O (event timeline + transitions), A (trajectory category: living_well/living_dying/dying_pivoted/dying_dying, trauma recurrence), P (prediction record: Company, Type, Category, Direction PASS/FAIL, Catalyst, Resolution source, Window start, Window end, Pass condition, Reasoning), Refs.
mcp startup: no servers
codex
I’m verifying the current aTyr event history and the stated FDA/clinical milestones first, then I’ll compress that into the SOAP format you requested.
🌐 Searching the web...
🌐 Searched: aTyr Pharma efzofitimod Phase 3 miss primary secondary endpoints press release 2025 official
🌐 Searching the web...
🌐 Searched: site:investors.atyrpharma.com aTyr sarcoidosis new trial 2026 efzofitimod
🌐 Searching the web...
🌐 Searched: site:investors.atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results 2026
🌐 Searching the web...
🌐 Searched: finance: ATYR
🌐 Searching the web...
🌐 Searched: finance: ATYR
codex
**S**  
aTyr Pharma is a single-asset salvage story around efzofitimod in pulmonary sarcoidosis after the September 15, 2025 Phase 3 EFZO-FIT miss on the primary steroid-reduction endpoint, despite nominally positive secondary/symptom signals and maintained lung function. The stock has already absorbed the major failure shock, and the next decisive inflection is the FDA Type C meeting scheduled for mid-April 2026. For this prospective call, the key question is not whether efzofitimod shows some residual activity, but whether FDA feedback is constructive enough, and management is funded/confident enough, to publicly announce a new sarcoidosis trial by September 30, 2026. Base case: that bar is still high.

**O**  
Event timeline:
- 2021-2022: efzofitimod established early proof-of-concept in pulmonary sarcoidosis and advanced into the pivotal EFZO-FIT Phase 3 program.
- March 6, 2025: fourth DSMB review reported no new safety concerns for EFZO-FIT.
- September 15, 2025: aTyr announced EFZO-FIT topline data; primary endpoint missed, while KSQ-Lung and combined symptom/steroid-withdrawal measures were reported as nominal positives because hierarchical testing stopped at the failed primary.
- September 15, 2025 onward: company framed results as evidence of drug activity and said it would engage FDA on path forward.
- February 3, 2026: aTyr announced FDA accepted its meeting request and scheduled a Type C meeting for mid-April 2026.
- March 2026: 10-K states cash/investments of about $80.9 million as of December 31, 2025, with runway for at least one year from filing, but no announced new sarcoidosis study yet.

Transitions:
- `registrational optimism -> failed pivotal`
- `failed pivotal -> post hoc/secondary-endpoint salvage narrative`
- `salvage narrative -> regulatory gatekeeping`
- `regulatory gatekeeping -> possible redesign, but only if FDA feedback and financing align`

**A**  
Trajectory category: `dying_pivoted`  
Trauma recurrence: `high`

Rationale: the lead program was materially damaged by a pivotal miss, the company remains heavily consolidated around efzofitimod, and the current strategy is effectively a regulatory reset rather than a position of strength. This is not `dying_dying` because the company still has signal, cash, and an active FDA process; it is not `living_dying` because the core franchise already broke. Trauma recurrence is high because management is incentivized to reinterpret secondary signals and pursue a narrower/reworked trial thesis after a major failure.

**P**  
Company: aTyr Pharma (`ATYR`)  
Type: Real prospective prediction, Run 1  
Category: Event / clinical-regulatory  
Direction: `FAIL`  
Catalyst: aTyr announces a new sarcoidosis clinical trial (any phase, any design) by September 30, 2026  
Resolution source: company press release on investor site and/or SEC 8-K  
Window start: March 20, 2026  
Window end: September 30, 2026  
Pass condition: press release or 8-K announcing a new sarcoidosis clinical trial within the window  
Reasoning: The April 2026 Type C meeting is necessary but probably not sufficient. After a failed Phase 3 primary endpoint, FDA may permit further study, but translating that into a public new-trial announcement by September 30, 2026 likely requires fast alignment on design, internal conviction that the secondary signals justify reinvestment, and enough balance-sheet flexibility to commit publicly. aTyr still has cash, but not obviously enough to make a broad, confident restart trivial, and the company has not yet announced a new sarcoidosis study as of March 20, 2026. The most likely near-term outcome is discussion of “path forward” or continued evaluation rather than a formal new-trial announcement inside the window.

**Refs**  
- [aTyr Phase 3 topline press release, Sep. 15, 2025](https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study)  
- [aTyr 8-K on Phase 3 results, Sep. 15, 2025](https://www.sec.gov/Archives/edgar/data/0001339970/000119312525202865/atyr-20250915.htm)  
- [aTyr Type C meeting announcement, Feb. 3, 2026](https://www.nasdaq.com/press-release/atyr-pharma-announces-scheduling-fda-type-c-meeting-discuss-efzofitimod-program)  
- [aTyr 2025 Form 10-K, filed March 2026](https://www.sec.gov/Archives/edgar/data/0001339970/000133997026000008/atyr-20251231.htm)  
- [aTyr DSMB update, Mar. 6, 2025](https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-fourth-positive-dsmb-review-efzofitimod)
tokens used
15,984
**S**  
aTyr Pharma is a single-asset salvage story around efzofitimod in pulmonary sarcoidosis after the September 15, 2025 Phase 3 EFZO-FIT miss on the primary steroid-reduction endpoint, despite nominally positive secondary/symptom signals and maintained lung function. The stock has already absorbed the major failure shock, and the next decisive inflection is the FDA Type C meeting scheduled for mid-April 2026. For this prospective call, the key question is not whether efzofitimod shows some residual activity, but whether FDA feedback is constructive enough, and management is funded/confident enough, to publicly announce a new sarcoidosis trial by September 30, 2026. Base case: that bar is still high.

**O**  
Event timeline:
- 2021-2022: efzofitimod established early proof-of-concept in pulmonary sarcoidosis and advanced into the pivotal EFZO-FIT Phase 3 program.
- March 6, 2025: fourth DSMB review reported no new safety concerns for EFZO-FIT.
- September 15, 2025: aTyr announced EFZO-FIT topline data; primary endpoint missed, while KSQ-Lung and combined symptom/steroid-withdrawal measures were reported as nominal positives because hierarchical testing stopped at the failed primary.
- September 15, 2025 onward: company framed results as evidence of drug activity and said it would engage FDA on path forward.
- February 3, 2026: aTyr announced FDA accepted its meeting request and scheduled a Type C meeting for mid-April 2026.
- March 2026: 10-K states cash/investments of about $80.9 million as of December 31, 2025, with runway for at least one year from filing, but no announced new sarcoidosis study yet.

Transitions:
- `registrational optimism -> failed pivotal`
- `failed pivotal -> post hoc/secondary-endpoint salvage narrative`
- `salvage narrative -> regulatory gatekeeping`
- `regulatory gatekeeping -> possible redesign, but only if FDA feedback and financing align`

**A**  
Trajectory category: `dying_pivoted`  
Trauma recurrence: `high`

Rationale: the lead program was materially damaged by a pivotal miss, the company remains heavily consolidated around efzofitimod, and the current strategy is effectively a regulatory reset rather than a position of strength. This is not `dying_dying` because the company still has signal, cash, and an active FDA process; it is not `living_dying` because the core franchise already broke. Trauma recurrence is high because management is incentivized to reinterpret secondary signals and pursue a narrower/reworked trial thesis after a major failure.

**P**  
Company: aTyr Pharma (`ATYR`)  
Type: Real prospective prediction, Run 1  
Category: Event / clinical-regulatory  
Direction: `FAIL`  
Catalyst: aTyr announces a new sarcoidosis clinical trial (any phase, any design) by September 30, 2026  
Resolution source: company press release on investor site and/or SEC 8-K  
Window start: March 20, 2026  
Window end: September 30, 2026  
Pass condition: press release or 8-K announcing a new sarcoidosis clinical trial within the window  
Reasoning: The April 2026 Type C meeting is necessary but probably not sufficient. After a failed Phase 3 primary endpoint, FDA may permit further study, but translating that into a public new-trial announcement by September 30, 2026 likely requires fast alignment on design, internal conviction that the secondary signals justify reinvestment, and enough balance-sheet flexibility to commit publicly. aTyr still has cash, but not obviously enough to make a broad, confident restart trivial, and the company has not yet announced a new sarcoidosis study as of March 20, 2026. The most likely near-term outcome is discussion of “path forward” or continued evaluation rather than a formal new-trial announcement inside the window.

**Refs**  
- [aTyr Phase 3 topline press release, Sep. 15, 2025](https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study)  
- [aTyr 8-K on Phase 3 results, Sep. 15, 2025](https://www.sec.gov/Archives/edgar/data/0001339970/000119312525202865/atyr-20250915.htm)  
- [aTyr Type C meeting announcement, Feb. 3, 2026](https://www.nasdaq.com/press-release/atyr-pharma-announces-scheduling-fda-type-c-meeting-discuss-efzofitimod-program)  
- [aTyr 2025 Form 10-K, filed March 2026](https://www.sec.gov/Archives/edgar/data/0001339970/000133997026000008/atyr-20251231.htm)  
- [aTyr DSMB update, Mar. 6, 2025](https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-fourth-positive-dsmb-review-efzofitimod)
